

April 30, 2024

The Listing Department BSE Limited Phiroze Jeejebhoy Towers, Dalal Street, Fort, Mumbai – 400001 BSE Scrip Code: 543427 The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5<sup>th</sup> Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that one of the subsidiary of the Company i.e., Optival Health Solutions Private Limited has received suspension order from Assistant Director, Drugs Control Administration, Bangalore Circle- Mysore, Karnataka under Drugs and Cosmetic Act, 1940 and Drugs and Cosmetics Rules, 1945 temporarily suspending the operations for four days of its store situated at Brindavan Extension, 1st Phase, Karnataka. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details is given below:

Name(s) of the Authority:	Nature and details of the action(s) taken, initiated or order(s) passed		violation(s) / contravention(s) committed or alleged	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Director, Drugs Control Administration, Bangalore Circle- Mysore, Karnataka	Temporary suspension of Drug License for four days of a store situated at Shop No. 1,2 & 3 #21, 3rd Main, Brindavan Extension, 1st Phase, Karnataka	Order received on 29.04.2024	Under Rule 65(4)(3)(i), 65(4)(4)(ii), 65(4)(4), 65(6), 65(3)(1), 65(3)(1)(h), 65(17), 65(11) under the Drug and Cosmetic Act, 1940 and Rules, 1945	Potential Revenue Loss of Rs~ 1.93 Lacs.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava Company Secretary FCS 7460